Nuvelo(NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo(NUVO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: FiloF who wrote (57)	1/9/2006 7:38:44 AM
From: Arthur Radley	Read Replies (1) of 140

NUVO is giving a pipeline update today at the JP Morgan conference, however, this tidbit about expanding the rNAPc2 drug into the cancer arena is very intriguing...this is the first mention to my knowledge about this potential... ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ The Company also plans to expand the clinical development program for its second drug candidate, rNAPc2, an inhibitor of the factor VIIa/tissue factor protease complex. This complex has been shown to play a role in the cellular signaling of both metastasis and angiogenesis in a variety of cancers. The Company plans to investigate the role of rNAPc2 as a potential cancer therapy in 2006. In addition, Nuvelo plans to complete its Phase 2 heparin replacement trial in the first half of 2006, investigating the role of rNAPc2 as an anticoagulant in patients with acute coronary syndrome.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next